Investor Presentaiton

World-class Fully Integrated Biopharmaceutical Platform to Address Unmet Medical Needs with Innovative Therapies Robust Pipeline Across Novel Therapeutics Discovery Deep understanding in immunology and unique strength in antibody engineering CMC (Manufacturing & Quality) In-house manufacturing with large capacity Oncology 10 backbone and high potential targets: PD-1, CTLA-4, CD47, LAG- 3, TIGIT, etc. Leading technology: cell therapy, multi-specific antibody, ADC Fully Integrated Biopharmaceutical Platform Clinical Development Robust pipeline in different clinical stages Strong execution capability Non-oncology Highly competitive and promising franchise in autoimmune, metabolic and ophthalmology • Commercialization Extensive network covering 4,700 hospitals and 1,000 DTP/Pharmacies ~2,000 sales & marketing team Innovent Target on Unmet Medical Needs Number of new cancer cases in 2020 (Global) % 11.7% 11.4% 10.0% 7.3% 5.6% Number of new cancer cases in 2020 (China) 17.9% 12.2% 10.5% 9.1% 9.0% # 2,261,419 2,206,771 815,563 1,931,590 1,414,259 555,477 1,089,103 478,508 416,371 410,038 Lung Colorectum Stomach Breast Humira Keytruda Revlimid Eliquis Imbruvica Confidential Copyright©2021 Innovent Biologics Source: WHO IARC 2020 report; Fierce Pharma, Evaluate Pharma Autoimmune Opdivo Eylea Stelara US$bn 20 Biktarvy 14 12 9 Xarelto Breast Lung Colorectum Prostate Stomach Top 20 Drug Sales in 2020 (Global) 8 8 8 8 7 7 6 6 5 5 55 5 4 Enbrel Prevnar 13 Ophthalmology Avastin Ibrance Trulicity Ocrevus Rituxan Metabolic Tagrisso Standi CO 4 Remicade Liver

View entire presentation